Usefulness of Low-dose Methotrexate Monotherapy for Treating Sarcoidosis
-
- Isshiki Takuma
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Yamaguchi Tetsuo
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Yamada Yoshihito
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Maemura Keita
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Makita Kosuke
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Takeshima Hideyuki
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Hirasawa Yasutaka
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Yamaguchi Yoko
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Hosoki Keisuke
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Suzuki Mika
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Kono Chiyoko
- Department of Chest Medicine, Japan Railway Tokyo General Hospital, Japan
-
- Terada Jiro
- Department of Respirology, Graduate School of Medicine, Chiba University, Japan
-
- Tatsumi Koichiro
- Department of Respirology, Graduate School of Medicine, Chiba University, Japan
この論文をさがす
抄録
Objective Methotrexate (MTX) is a cytotoxic agent that is commonly employed as an alternative to corticosteroids to treat sarcoidosis, although the proper use and efficacy of MTX as a single agent remain unclear.<br> Methods The clinical records of patients newly diagnosed with sarcoidosis who were admitted to our institution between 2000 and 2009 were reviewed. Among these patients, 26 received 7.5 mg of MTX per week as a single agent, and the independent effects of MTX were analyzed.<br> Results Six of the 26 patients (23%) exhibited an improvement of sarcoidosis-related lesions. The skin lesions demonstrated a relatively higher response rate (37%) than the pulmonary lesions (9%). Ten of the 26 patients (39%) experienced adverse effects, mostly mild hepatotoxicity. No severe adverse effects, including irreversible hepatotoxicity, were observed.<br> Conclusion Although the efficacy of low-dose MTX monotherapy for sarcoidosis in this study was not high (23%), some patients exhibited definite improvements, and the drug proved to be safe, suggesting its possible benefits as a single agent for treating sarcoidosis.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 52 (24), 2727-2732, 2013
一般社団法人 日本内科学会
